Trial · NCT01955382

Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria

NCT01955382, Phase 2, Completed, National Institute of Allergy and Infectious Diseases (NIAID); results first posted 2018-02-06

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria. Trials, record NCT01955382. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01955382

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria
NCT number: NCT01955382
Status: Completed
Phases: Phase 2
Enrollment: 70 participants, actual
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions: Malaria, Severe Malaria
Interventions: Actidose Aqua, Artesunate, Amodiaquine
First posted: 2013-10-07
Last updated: 2018-02-06
Results first posted: 2018-02-06

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Parasite Clearance Half-life	During patient treatment	To compare parasite clearance half-life in patients treated with IV AS + oAC or IV AS alone; parasite clearance half-life is the time it takes for the parasite density to decrease by half, and can be assessed by analysing frequent parasite density counts at 0, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, and 48 hours after initiating treatment.
Primary	Safety	During patient treatment up to 48 hours	To assess the safety of adjunct treatment with oAC; specifically, children were hospitalized while their vital signs were measured, IV site inspected, state of consciousness assessed, and selected symptoms (nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and dizziness) surveyed at 0, 2, 4, 6, 8, and 12 hours, and then every 6 hours until 48 hours or until parasitemia became undetectable (one negative thick blood film), whichever was later.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Parasite Clearance Half-life	During patient treatment		Hours	MEAN
PRIMARY	Safety	During patient treatment up to 48 hours	Children who received treatment per protocol	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Parasite Clearance Half-life	AS + oAC	1.733	Standard Deviation 0.7206	Hours
Parasite Clearance Half-life	AS Only (Water)	1.973	Standard Deviation 0.6221	Hours
Safety	AS + oAC	35		Participants
Safety	AS Only (Water)	35		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	AS + oAC	35
Overall Study	STARTED	AS Only (Water)	35
Overall Study	COMPLETED	AS + oAC	35
Overall Study	COMPLETED	AS Only (Water)	35
Overall Study	NOT COMPLETED	AS + oAC	0
Overall Study	NOT COMPLETED	AS Only (Water)	0

Source ClinicalTrials.gov

Adverse events10

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal pain	Gastrointestinal disorders	AS + oAC	2	35	2
other	Abdominal pain	Gastrointestinal disorders	AS Only (Water)	3	35	3
other	Constipation	Gastrointestinal disorders	AS + oAC	2	35	2
other	Constipation	Gastrointestinal disorders	AS Only (Water)	0	35	0
other	Nausea	Gastrointestinal disorders	AS + oAC	1	35	1
other	Nausea	Gastrointestinal disorders	AS Only (Water)	0	35	0
other	Cough	Respiratory, thoracic and mediastinal disorders	AS + oAC	0	35	0
other	Cough	Respiratory, thoracic and mediastinal disorders	AS Only (Water)	1	35	1
other	Hypotension	Vascular disorders	AS + oAC	1	35	1
other	Hypotension	Vascular disorders	AS Only (Water)	1	35	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	AS + oAC
Total, all-cause mortality	AS Only (Water)
Total, other adverse events	AS + oAC	6	35
Total, other adverse events	AS Only (Water)	5	35
Total, serious adverse events	AS + oAC	0	35
Total, serious adverse events	AS Only (Water)	0	35

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
AS + oAC vs AS Only (Water): Safety	Trial comparisons
AS + oAC vs AS Only (Water): serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01955382

GET https://conductscience.org/api/trials/v1/NCT01955382/registered

API reference For AI assistants